Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Hofmann

Showing results (511-520 of 525) with videos related to

Pageof 53
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2025
SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS<sup>G12D</sup> inhibitor in KRAS LUADFernando C Baltanás, Maximilian Kramer-Drauberg, Rósula García-Navas, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 11, 2015
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemiaDorothea Rudolph, Maria Antonietta Impagnatiello, Claudia Blaukopf, et al.
Oncogene|August 30, 2001
No evidence of somatic FGFR3 mutation in various types of carcinomaM Karoui, H Hofmann-Radvanyi, U Zimmermann, et al.
British Journal of Cancer|March 18, 2004
Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastasesM Karoui, C Tresallet, C Julie, et al.
Cancer Research|October 22, 2024
SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung AdenocarcinomaBrianna R Daley, Nancy E Sealover, Bridget A Finniff, et al.
Cell Reports. Medicine|November 2, 2024
Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanomaMichelangelo Marasco, Dinesh Kumar, Tessa Seale, et al.
Allergy|November 2, 2023
Combining avidin with CD63 improves basophil activation test accuracy in classifying peanut allergyNicolas Castaño, Kaiser Chua, Abhinav Kaushik, et al.
Cancer Discovery|June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathwayPietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Cancer Research Communications|May 10, 2024
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy ResponseRobert J Norgard, Pratha Budhani, Sarah A O'Brien, et al.
Pageof 53

Showing results (511-520 of 525) with videos related to

Sort By:
Pageof 53
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2025
SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS<sup>G12D</sup> inhibitor in KRAS LUADFernando C Baltanás, Maximilian Kramer-Drauberg, Rósula García-Navas, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 11, 2015
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemiaDorothea Rudolph, Maria Antonietta Impagnatiello, Claudia Blaukopf, et al.
Oncogene|August 30, 2001
No evidence of somatic FGFR3 mutation in various types of carcinomaM Karoui, H Hofmann-Radvanyi, U Zimmermann, et al.
British Journal of Cancer|March 18, 2004
Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastasesM Karoui, C Tresallet, C Julie, et al.
Cancer Research|October 22, 2024
SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung AdenocarcinomaBrianna R Daley, Nancy E Sealover, Bridget A Finniff, et al.
Cell Reports. Medicine|November 2, 2024
Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanomaMichelangelo Marasco, Dinesh Kumar, Tessa Seale, et al.
Allergy|November 2, 2023
Combining avidin with CD63 improves basophil activation test accuracy in classifying peanut allergyNicolas Castaño, Kaiser Chua, Abhinav Kaushik, et al.
Cancer Discovery|June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathwayPietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Cancer Research Communications|May 10, 2024
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy ResponseRobert J Norgard, Pratha Budhani, Sarah A O'Brien, et al.
Pageof 53